• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌和卵巢癌中-和-突变的转录组图谱。

Transcriptome Patterns of - and - Mutated Breast and Ovarian Cancers.

机构信息

Group of Bioinformatics, Institute of Molecular Biology National Academy of Sciences of Armenia, 0014 Yerevan, Armenia.

Institute of Biomedicine and Pharmacy, Russian-Armenian University, 0051 Yerevan, Armenia.

出版信息

Int J Mol Sci. 2021 Jan 28;22(3):1266. doi: 10.3390/ijms22031266.

DOI:10.3390/ijms22031266
PMID:33525353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7865215/
Abstract

Mutations in the and genes are known risk factors and drivers of breast and ovarian cancers. So far, few studies have been focused on understanding the differences in transcriptome and functional landscapes associated with the disease (breast vs. ovarian cancers), gene ( vs. ), and mutation type (germline vs. somatic). In this study, we were aimed at systemic evaluation of the association of and germline and somatic mutations with gene expression, disease clinical features, outcome, and treatment. We performed mutation centered RNA-seq data analysis of breast and ovarian cancers from the TCGA repository using transcriptome and phenotype "portrayal" with multi-layer self-organizing maps and functional annotation. The results revealed considerable differences in - and -dependent transcriptome landscapes in the studied cancers. Furthermore, our data indicated that somatic and germline mutations for both genes are characterized by deregulation of different biological functions and differential associations with phenotype characteristics and poly(ADP-ribose) polymerase (PARP)-inhibitor gene signatures. Overall, this study demonstrates considerable variation in transcriptomic landscapes of breast and ovarian cancers associated with the affected gene ( vs. ), as well as the mutation type (somatic vs. germline). These results warrant further investigations with larger groups of mutation carriers aimed at refining the understanding of molecular mechanisms of breast and ovarian cancers.

摘要

和 基因突变是乳腺癌和卵巢癌的已知风险因素和驱动因素。到目前为止,很少有研究集中于理解与疾病(乳腺癌与卵巢癌)、基因(和 )和突变类型(种系与体细胞)相关的转录组和功能景观的差异。在这项研究中,我们旨在系统评估 种系和体细胞突变与基因表达、疾病临床特征、预后和治疗的关联。我们使用转录组和表型“描绘”多层自组织映射和功能注释,对 TCGA 数据库中的乳腺癌和卵巢癌进行了以 突变为中心的 RNA-seq 数据分析。结果显示,在研究的癌症中,和 依赖性转录组景观存在相当大的差异。此外,我们的数据表明,这两个基因的体细胞和种系突变都表现出不同的生物学功能失调,与表型特征和聚(ADP-核糖)聚合酶(PARP)抑制剂基因特征的相关性也不同。总的来说,这项研究表明,乳腺癌和卵巢癌的转录组景观与受影响的基因(和 )以及突变类型(体细胞与种系)存在相当大的差异。这些结果需要进一步对更大的突变携带者群体进行研究,以深入了解乳腺癌和卵巢癌的分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/34a2bbd4f608/ijms-22-01266-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/5aeb0d2d7722/ijms-22-01266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/3ca26332c2e9/ijms-22-01266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/a3227526a8ce/ijms-22-01266-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/21612f5b8b20/ijms-22-01266-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/3c8c7d36776a/ijms-22-01266-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/e19d5c5da65f/ijms-22-01266-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/42a5a3b393bb/ijms-22-01266-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/bbf81763abfa/ijms-22-01266-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/34a2bbd4f608/ijms-22-01266-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/5aeb0d2d7722/ijms-22-01266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/3ca26332c2e9/ijms-22-01266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/a3227526a8ce/ijms-22-01266-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/21612f5b8b20/ijms-22-01266-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/3c8c7d36776a/ijms-22-01266-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/e19d5c5da65f/ijms-22-01266-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/42a5a3b393bb/ijms-22-01266-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/bbf81763abfa/ijms-22-01266-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c5b/7865215/34a2bbd4f608/ijms-22-01266-g009.jpg

相似文献

1
Transcriptome Patterns of - and - Mutated Breast and Ovarian Cancers.乳腺癌和卵巢癌中-和-突变的转录组图谱。
Int J Mol Sci. 2021 Jan 28;22(3):1266. doi: 10.3390/ijms22031266.
2
Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.耐药性乳腺癌或卵巢癌循环游离 DNA 中的多种和回复突变。
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
3
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.398 例卵巢癌患者的 BRCA1 和 BRCA2 突变与临床解读:与相似人群中乳腺癌变异体的比较。
Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.
4
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.HRDetect是一种基于突变特征的BRCA1和BRCA2缺陷预测指标。
Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
5
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.BRCA1/2 种系和体细胞突变景观在高级别浆液性卵巢癌患者中的分析。
BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
6
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.乳腺癌和卵巢癌中 BRCA 的表达与突变:生物信息学分析证据。
Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
7
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.BRCA1 和 BRCA2 相关突变:在卵巢癌中的治疗意义。
Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.
8
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.BRCA1/2 信号通路与乳腺癌和卵巢癌同源重组缺陷
Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
9
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.奥拉帕利治疗复发性高级别浆液性或低分化卵巢癌或三阴性乳腺癌患者的疗效:一项多中心、开放标签、非随机的 2 期临床试验。
Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.
10
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.中国卵巢癌患者的 BRCA1 和 BRCA2 突变:BRCA1 中的种族相关突变与卵巢癌风险增加相关。
Int J Cancer. 2017 May 1;140(9):2051-2059. doi: 10.1002/ijc.30633. Epub 2017 Feb 23.

引用本文的文献

1
Assigning Transcriptomic Subtypes to Chronic Lymphocytic Leukemia Samples Using Nanopore RNA-Sequencing and Self-Organizing Maps.使用纳米孔RNA测序和自组织映射为慢性淋巴细胞白血病样本分配转录组亚型
Cancers (Basel). 2025 Mar 13;17(6):964. doi: 10.3390/cancers17060964.
2
Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.变革个性化医疗:与多组学数据生成的协同作用、主要障碍及未来展望
Biomedicines. 2024 Nov 30;12(12):2750. doi: 10.3390/biomedicines12122750.
3
Navigating the Frontiers of Machine Learning in Neurodegenerative Disease Therapeutics.

本文引用的文献

1
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.靶向免疫抑制性巨噬细胞可克服BRCA1相关三阴性乳腺癌中的PARP抑制剂耐药性。
Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14.
2
DNA Damage Response and Immune Defense.DNA 损伤反应与免疫防御
Int J Mol Sci. 2020 Oct 12;21(20):7504. doi: 10.3390/ijms21207504.
3
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.候选 BRCA 样基因中的种系和体细胞事件对乳腺癌特征的影响。
探索机器学习在神经退行性疾病治疗中的前沿领域。
Pharmaceuticals (Basel). 2024 Jan 25;17(2):158. doi: 10.3390/ph17020158.
4
Temporal changes of gene expression in health, schizophrenia, bipolar disorder, and major depressive disorder.健康、精神分裂症、双相情感障碍和重度抑郁症中基因表达的时间变化。
Schizophrenia (Heidelb). 2024 Feb 17;10(1):19. doi: 10.1038/s41537-024-00443-7.
5
Unsupervised analysis of whole transcriptome data from human pluripotent stem cells cardiac differentiation.人类多能干细胞心脏分化的全转录组数据无监督分析。
Sci Rep. 2024 Feb 7;14(1):3110. doi: 10.1038/s41598-024-52970-z.
6
A transcriptional response to replication stress selectively expands a subset of Brca2-mutant mammary epithelial cells.复制压力诱导的转录反应选择性扩增了一组特定的 Brca2 突变型乳腺上皮细胞。
Nat Commun. 2023 Aug 25;14(1):5206. doi: 10.1038/s41467-023-40956-w.
7
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.迈向更全面的卵巢癌同源重组缺陷检测,第1部分:技术考量
Cancers (Basel). 2022 Feb 23;14(5):1132. doi: 10.3390/cancers14051132.
8
Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer.利用基因组学、转录组学和表观基因组学来理解卵巢癌的生物学特性和化疗耐药性。
Cancers (Basel). 2021 Aug 10;13(16):4029. doi: 10.3390/cancers13164029.
PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197. eCollection 2020.
4
High expression of ZNF93 promotes proliferation and migration of ovarian cancer cells and relates to poor prognosis.ZNF93的高表达促进卵巢癌细胞的增殖和迁移,并与不良预后相关。
Int J Clin Exp Pathol. 2020 May 1;13(5):944-953. eCollection 2020.
5
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.从免疫角度探索 BRCA1 和 BRCA2 种系突变相关的乳腺癌和卵巢癌。
BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
6
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.聚(ADP-核糖)聚合酶(PARP)抑制剂作为治疗药物:超越PAR化修饰调控
Cancers (Basel). 2020 Feb 8;12(2):394. doi: 10.3390/cancers12020394.
7
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies.PARP-1和PARP-2的免疫调节作用:对以PARP为中心的癌症治疗的影响。
Cancers (Basel). 2020 Feb 8;12(2):392. doi: 10.3390/cancers12020392.
8
GP130 Cytokines in Breast Cancer and Bone.乳腺癌与骨骼中的GP130细胞因子
Cancers (Basel). 2020 Jan 31;12(2):326. doi: 10.3390/cancers12020326.
9
Differentially expressed genes and key molecules of -mutant breast cancer: evidence from bioinformatics analyses.-突变型乳腺癌的差异表达基因和关键分子:来自生物信息学分析的证据
PeerJ. 2020 Jan 21;8:e8403. doi: 10.7717/peerj.8403. eCollection 2020.
10
Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.卵巢癌中 DNA 损伤修复基因体细胞突变与免疫相关基因表达的相关性。
Cancer Med. 2020 Mar;9(6):2190-2200. doi: 10.1002/cam4.2849. Epub 2020 Jan 28.